HC Wainwright Issues Positive Outlook for Vericel Earnings

Vericel Corporation (NASDAQ:VCEL) – HC Wainwright upped their Q4 2026 EPS estimates for Vericel in a report issued on Friday, November 6th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings of $0.62 per share for the quarter, up from their previous forecast of $0.50. HC Wainwright currently has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.54 per share. HC Wainwright also issued estimates for Vericel’s Q4 2027 earnings at $0.53 EPS.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.21. The business had revenue of $85.37 million during the quarter, compared to analysts’ expectations of $77.95 million. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The firm’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 EPS.

Several other equities analysts have also recently issued reports on the company. TD Cowen boosted their target price on Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Vericel in a report on Thursday, October 29th. Wall Street Zen raised Vericel from a “buy” rating to a “strong-buy” rating in a report on Saturday. Truist Financial increased their target price on Vericel from $52.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Canaccord Genuity Group set a $60.00 target price on Vericel in a research note on Thursday, July 30th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Vericel currently has an average rating of “Moderate Buy” and an average target price of $60.80.

Vericel Trading Up 6.9%

Vericel stock opened at $58.39 on Monday. The firm has a 50-day moving average of $41.36 and a 200-day moving average of $39.00. The firm has a market cap of $2.99 billion, a P/E ratio of 96.77 and a beta of 1.08. Vericel has a 1-year low of $28.95 and a 1-year high of $59.48.

Insiders Place Their Bets

In other news, Director Robert Zerbe sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $52.23, for a total value of $156,690.00. Following the transaction, the director owned 32,995 shares in the company, valued at approximately $1,723,328.85. This represents a 8.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Sean Flynn sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $51.92, for a total transaction of $778,800.00. Following the completion of the transaction, the insider owned 1,990 shares in the company, valued at approximately $103,320.80. This represents a 88.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 22,000 shares of company stock valued at $1,128,340. Insiders own 7.60% of the company’s stock.

Institutional Trading of Vericel

Institutional investors and hedge funds have recently modified their holdings of the business. Lisanti Capital Growth LLC purchased a new stake in Vericel in the second quarter worth approximately $5,356,000. Man Group plc bought a new stake in Vericel in the 2nd quarter worth approximately $2,998,000. Scholtz & Company LLC purchased a new stake in Vericel during the 2nd quarter valued at $2,287,000. Bank of New York Mellon Corp purchased a new stake in Vericel during the 2nd quarter valued at $12,366,000. Finally, Madison Asset Management LLC purchased a new stake in Vericel during the 2nd quarter valued at $2,230,000.

Vericel Company Profile

Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States.

Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.

The company traces its roots to Aastrom Biosciences and adopted the Vericel name in 2014.